预约演示
更新于：2025-01-13
Phytonadione
维生素K1
更新于：2025-01-13
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1955-09-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C31H46O2 |
InChIKeyMBWXNTAXLNYFJB-NKFFZRIASA-N |
CAS号84-80-0 |
关联
91
项与 维生素K1 相关的临床试验NCT06385275
The Role of Vitamin K on Knee Osteoarthritis Outcomes
CTR20243843
维生素K1注射液在健康受试者中随机、开放、两制剂、两序列、交叉、静脉注射给药的生物等效性试验
CTR20243597
维生素K1注射液在健康受试者中的随机、开放、两周期、两序列、双交叉、静脉注射给药生物等效性试验
100 项与 维生素K1 相关的临床结果
登录后查看更多信息
100 项与 维生素K1 相关的转化医学
登录后查看更多信息
100 项与 维生素K1 相关的专利（医药）
登录后查看更多信息
15,611
项与 维生素K1 相关的文献（医药）2025-03-01AMERICAN JOURNAL OF CARDIOLOGY
Direct Oral Anticoagulants Versus Warfarin for the Treatment of Left Ventricular Thrombus: A Multicenter Retrospective Observational Study
Article
作者: Prasad, Rohan Madhu ; Boumegouas, Manel ; Clay, Shannon ; Al-Abcha, Abdullah ; Salam, Mohammad Fahad ; Abela, George S ; Wang, Ling ; Srivastava, Shaurya ; Saleh, Yehia ; Essa, Essa M
Vitamin K antagonists remain the mainstay of therapy in patients with left ventricular thrombus (LVT) because the efficacy of direct oral anticoagulants (DOACs) is not well-established. We performed a multicenter retrospective analysis of adults admitted between January 2015 and December 2021 and diagnosed with LVT to compare the safety and efficacy of warfarin versus DOACs. The primary outcome was thrombus resolution. Secondary outcomes included all-cause mortality, bleeding events, and stroke or systemic embolism. A total of 189 patients were included. The rate of thrombus resolution was similar in patients with LVT treated with DOACs compared with those treated with warfarin (DOACs 73.9%vs warfarin 68.5%, p = 0.489). In addition, all-cause mortality (DOACs 13.04% vs warfarin 9.79%, p = 0.583), bleeding events (DOACs 19.57% vs warfarin 13.99%, p = 0.361), and stroke or systemic embolism (DOACs 10.87% vs warfarin 15.38%, p = 0.446) were all similar in the 2 groups. In the propensity-matched group, 90 patients were included. Multivariate analysis showed no significant difference of using warfarin or DOACs on thrombus resolution (odds ratio [OR] 0.94, 95% confidence interval [CI] 0.858 to 1.029, p = 0.18), all-cause mortality (OR 1.032, 95% CI 0.906 to 1.176, p = 0.6354), bleeding events (OR 1.694, 95% CI 0.168 to 17.097, p = 0.655), or stroke or systemic embolism (OR 1.947, 95% CI 0.087 to 4.756, p = 0.6747). In conclusion, in our retrospective analysis, DOACs had similar efficacy and safety compared with warfarin in the treatment of LVT.
2025-03-01JOURNAL OF MOLECULAR GRAPHICS & MODELLING
Absorption study of fat-soluble vitamins into dipalmitoylphosphatidylcholine (DPPC) bilayer by MD simulations
Article
作者: Na Nakorn, Narissara ; Muensritharam, Laksamee ; Boonyarat, Warabhorn ; Phromchaloem, Chanya
Retinol, α-tocopherol and phylloquinone (vitamins A, E, and K) are presented in high concentrations within the chloroplast and leaves of most plants. They are fat-soluble vitamins and absorb similarly to other dietary lipids. Because the molecular mechanism of retinol, α-tocopherol, and phylloquinone absorption is still unknown, this work aims to investigate the distribution of these vitamins at the water/membrane interface using molecular dynamics (MD) simulations. Structures and variations of the hydroxyl group in vitamins are the keys to the investigation of the absorption process. Binding orientations, favorable binding sites, interactions, and diffusion of vitamins were identified. All vitamins spontaneously penetrate the lipid bilayer. According to simulations, the formation of the hydrogen bonding interaction with the phosphate group of DPPC during absorption requires a hydroxyl group of retinol and tocopherol. Therefore, retinol has -OH group at the tail of the structure and shows the highest structural flexibility of retinol, broadest tilt angle toward the lipid membrane, and highest diffusion coefficient. Finally, retinol plugs its head group into the hydrocarbon core of the lipid bilayer. In the case of α-tocopherol, the hydroxyl at the head group produces α-tocopherol, which moves through one leaflet of the lipid membrane and is stabilized in the opposite leaflet. Interestingly, phylloquinone, a molecule without a hydroxyl group, stabilizes close to a phosphate group without hydrogen bond formation. The head group of phylloquinone penetrates at a precise tilting angle of 120°. High retention of phylloquinone inside gel-phase DPPC is suggested by its low diffusion coefficient. MD simulations reveal the characteristics of three fat-soluble vitamins during absorption through the phospholipid membrane. This information is useful as a guideline to improve the absorption of drugs along the membrane.
2025-02-01EUROPEAN JOURNAL OF NUTRITION
Investigating the associations between uncarboxylated matrix gla protein as a proxy for vitamin K status and cardiovascular disease risk factors in a general adult population
Article
作者: Dantoft, Thomas Meinertz ; Kofoed, Klaus Fuglsang ; Lauridsen, Julie Aaberg ; Linneberg, Allan ; Leth-Møller, Katja Biering ; Kårhus, Line Lund ; Møllehave, Line Tang
Abstract:
Purpose:
Vitamin K is an activator of vitamin K dependent proteins, one of which is the potent inhibitor of vascular calcification, matrix Gla protein (MGP). The purpose of this study is to investigate the association between an inverse proxy of functional vitamin K status, plasma dephospho-uncarboxylated MGP (dp-ucMGP), and cardiovascular disease risk factors (CVDRFs).
Methods:
In a cross-sectional population-based health examination study of 4,092 individuals aged 24–77 years, the vitamin K status was assessed using plasma dp-ucMGP. All participants were linked to Danish National Prescription Register to obtain information on the use of vitamin K antagonists. The associations between log2 transformed dp-ucMGP values and CVDRFs were determined using regression models adjusted for sex, age, lifestyle factors, kidney function and waist circumference.
Results:
Higher dp-ucMGP levels were associated with increased risk of central obesity (Odds Ratio (OR) 4.76, 95% Confidence Intervals (CI) 3.57–6.34), diabetes (OR 1.96, 95% CI 1.11–3.45), hyperlipidaemia (OR 1.43, 95% CI 1.01–2.03), and impaired kidney function (OR 9.83, 95% CI 5.49–17.59) per doubling in dp-ucMGP. Dp-ucMGP was not independently associated with hypertension or arterial stiffness.
Conclusion:
Higher dp-ucMGP levels were associated with central obesity, diabetes, hyperlipidaemia, and impaired kidney function. Prospective studies and intervention studies examining the effects of improving vitamin K status are needed to clarify the potential role of vitamin K in relation to these CVDRFs.
100 项与 维生素K1 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 维生素K缺乏症 | 日本 | 1962-03-31 | |
| 低凝血酶原血症 | 美国 | 1955-09-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 凝血障碍 | 申请上市 | 加拿大 | 2021-06-17 | |
| 维生素K缺乏性出血 | 临床1期 | 中国 | 2023-07-28 | |
| 皮疹 | 临床前 | 意大利 | 2011-05-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | - | 2023-08-28 | |||
N/A | 肝细胞癌 protein-induced by vitamin K absence (PIVKA-II) | serum a-fetoprotein (AFP) | 168 | 網鹽網顧繭構製窪蓋襯(製築窪獵積鑰鹹鏇鬱餘) = 鬱構觸顧齋積製繭衊鬱 艱醖餘憲遞選簾糧蓋鑰 (獵廠夢壓艱構鹹淵淵鬱 ) 更多 | - | 2022-06-25 | ||
(Control group) | 網鹽網顧繭構製窪蓋襯(製築窪獵積鑰鹹鏇鬱餘) = 衊構淵廠窪壓築醖鑰衊 艱醖餘憲遞選簾糧蓋鑰 (獵廠夢壓艱構鹹淵淵鬱 ) 更多 | ||||||
N/A | - | Vitamin K1 supplement | 蓋憲餘憲選築廠製構齋(齋衊範鹹糧選範鹹選繭) = 選獵選艱顧艱廠鹹獵艱 壓顧憲鹽繭積願壓醖醖 (鹹夢鏇繭選夢窪衊窪選 ) 更多 | - | 2015-08-01 | ||
(Placebo) | 蓋憲餘憲選築廠製構齋(齋衊範鹹糧選範鹹選繭) = 廠襯壓顧襯鏇醖觸鹽範 壓顧憲鹽繭積願壓醖醖 (鹹夢鏇繭選夢窪衊窪選 ) 更多 | ||||||
N/A | 16 | vitamin K+arnica | 繭遞夢鑰壓遞遞鏇範積(網襯鹽夢鹹築鹽簾遞淵) = 廠選鏇壓願餘窪遞製網 齋艱齋網願選構簾淵觸 (築衊顧衊築積衊膚廠簾, 艱製鹽淵壓壓鬱艱衊願 ~ 觸鏇選顧衊簾願繭壓顧) 更多 | - | 2012-12-04 | ||
临床1期 | 96 | (Warfarin Followed by Rivaroxaban (Xarelto, BAY59-7939)) | 築鏇齋選鹹膚獵鏇獵蓋(襯製繭膚選製齋衊衊衊) = 糧簾齋餘窪壓積齋鬱淵 範獵積膚範顧願繭網積 (遞壓衊願網醖觸夢鹽網, 夢遞鹽構網鬱網觸憲範 ~ 鹹範憲簾廠襯範糧築繭) 更多 | - | 2012-04-26 | ||
(Warfarin Followed by Placebo) | 築鏇齋選鹹膚獵鏇獵蓋(襯製繭膚選製齋衊衊衊) = 製衊鑰壓淵憲鑰壓膚選 範獵積膚範顧願繭網積 (遞壓衊願網醖觸夢鹽網, 選夢積醖鑰獵鹽齋餘憲 ~ 鬱壓膚獵糧積醖選製衊) 更多 | ||||||
N/A | 120 | 觸願鹹糧膚獵鹹蓋襯獵(繭獵範築構壓憲積獵夢) = 醖網醖淵鹽獵構鑰鬱簾 鬱顧衊齋遞鏇廠憲鏇鑰 (壓夢鹽顧簾艱觸廠廠鑰 ) | - | 2010-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用